相关产品推荐更多 >

Serine racemase Antibody 抗体,orb1338010,Biorbyt
¥9009
C16orf58 Rabbit Polyclonal Antibody 抗体,orb325507,Biorbyt
¥7254
Geminin Rabbit Polyclonal Antibody (FITC) 抗体,orb3147,Biorbyt
¥6201
NONO / p54nrb Rabbit mAb Antibody 抗体,orb1950667,Biorbyt
¥3042
Cdk5r1 Rabbit Polyclonal Antibody (Biotin) 抗体,orb2144860,Biorbyt
¥0
万千商家帮你免费找货
0 人在求购买到急需产品
相关阅读
源叶现货试剂/标准品,库存足,周末发货Cytoscape 教程来了!快速实现顶刊同款通路网络图五大应用案例:Mustang Q 膜层析应用全解析1 个小工具,一次性搞定流程图、质粒图谱和信号通路图- 详细信息
- 文献和实验
- 技术资料
- 抗体名:
KRT19 Antibody 抗体
- 抗体英文名:
KRT19 Antibody
- 靶点:
KRT19
- 浓度:
0.2 mg/mL
- 应用范围:
FC, IF, IHC-P, WB
- 宿主:
Mouse
- 适应物种:
Human
- 保质期:
12 months from date of receipt.
- 抗原来源:
详询
- 目录编号:
orb1252495
- 级别:
科研
- 库存:
99
- 供应商:
Biorbyt
- 标记物:
Unconjugated
- 克隆性:
Monoclonal
- 保存条件:
详询
- 形态:
Liquid
- 亚型:
IgG2a, kappa
- 免疫原:
详询
- 规格:
100 ug
类别: Antibodies
产品子类型: Primary Antibody
描述: KRT19 Antibody
克隆号: KRT19/799
别名: Keratin, type I cytoskeletal 19, Cytokeratin-19, CK-19, Keratin-19, K19, KRT19
应用说明: Flow Cytometry: 0.5-1 ug/million cells in 0.1mlImmunofluorescence: 1-2 µg/mLImmunohistochemistry (FFPE): 0.5-1 µg/mL for 30 min at RT (1)Prediluted format : incubate for 30 min at RT (2)Optimal dilution of the Cytokeratin 19 antibody should be determined by the researcher.1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 min2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
免疫原: Recombinant human KRT19 protein was used as the immunogen for the Cytokeratin 19 antibody.
防腐剂: PBS with 0.1 mg/ml rAlbumin and 0.05% sodium azide
纯化方法: Protein G affinity chromatography
研究领域: Signal Transduction
UniProt ID: P08727
保存条件: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
备注: For research use only.






产品子类型: Primary Antibody
描述: KRT19 Antibody
克隆号: KRT19/799
别名: Keratin, type I cytoskeletal 19, Cytokeratin-19, CK-19, Keratin-19, K19, KRT19
应用说明: Flow Cytometry: 0.5-1 ug/million cells in 0.1mlImmunofluorescence: 1-2 µg/mLImmunohistochemistry (FFPE): 0.5-1 µg/mL for 30 min at RT (1)Prediluted format : incubate for 30 min at RT (2)Optimal dilution of the Cytokeratin 19 antibody should be determined by the researcher.1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 min2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
免疫原: Recombinant human KRT19 protein was used as the immunogen for the Cytokeratin 19 antibody.
防腐剂: PBS with 0.1 mg/ml rAlbumin and 0.05% sodium azide
纯化方法: Protein G affinity chromatography
研究领域: Signal Transduction
UniProt ID: P08727
保存条件: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
备注: For research use only.

Formalin-fixed, paraffin-embedded human bladder carcinoma stained with Cytokeratin 19 antibody (KRT19/799).

Formalin-fixed, paraffin-embedded human cervical carcinoma stained with Cytokeratin 19 antibody (KRT19/799).

Formalin-fixed, paraffin-embedded human endometrial carcinoma stained with Cytokeratin 19 antibody (KRT19/799).

Formalin-fixed, paraffin-embedded human ovarian carcinoma stained with Cytokeratin 19 antibody (KRT19/799).

Formalin-fixed, paraffin-embedded human pancreas stained with Cytokeratin 19 antibody (KRT19/799).

SDS-PAGE Analysis of Purified, BSA-Free Cytokeratin 19 Antibody (clone KRT19/799). Confirmation of Integrity and Purity of the Antibody.
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
STM:广州医科大学刘铭/谢茂彬合作发现肝细胞癌的新潜在治疗靶点 Claudin 6
显示,CLDN6 可以稳定 YAP1,促进其核转位,从而活化 Hippo 通路。 IP 结果显示 CLDN6 与 YAP1 竞争性结合 TJP2 鉴于 CLDN6 是多次跨膜蛋白,但其不具有(或尚未发现?)配体结合结构域,难以设计小分子药物;而如果使用单抗的话,由于肝细胞癌具有复杂的微环境, T 细胞难以发挥足够的抗体依赖细胞毒性(ADCC)效应杀伤癌细胞。因此,作者设计了靶向 CLDN6 的抗体偶联药物(Antibody-Drug Conjugate, ADC),将细胞毒性药物 DM1 和 CLDN6 抗体
技术资料暂无技术资料 索取技术资料
KRT19 Antibody 抗体,orb1252495,Biorbyt
¥13338






